The strong revenue growth provides near-term support, but the stock will likely trade on execution around the Annual Meeting proposals (capital structure amendments) and any guidance on Q2 results. Monitor for proxy voting outcomes and potential dilution from the capital structure amendments.
Price Chart
Executive Summary
Picard Medical issued a pre-recorded stockholder presentation ahead of its July 17, 2026 Annual Meeting, highlighting an 85% YoY revenue increase, improved gross margins (28% from year-end 2025), and progress on the next-generation Emperor total artificial heart platform. The filing is a routine annual meeting communication; the strong revenue growth cited is notable for a sub-$20M market cap med-tech company, but the forward-looking development timeline (IDE submission in 2028, clinical study in 2029) is distant and uncertain.
Key Facts
- Annual Meeting scheduled for July 17, 2026; pre-recorded presentation made available on July 2, 2026.
- Revenue increased 85% year-over-year; U.S. revenue up 116%.
- Gross margin improved to 28% from year-end 2025.
- Next-generation Emperor platform development: IDE submission planned for 2028, clinical study intent in 2029.
- Proposals at Annual Meeting include election of directors, capital structure amendments, ratification of auditors, advisory compensation votes.
- Interim CEO Richard Fang acknowledges 'recent leadership changes'.
Financial Impact
Revenue up 85% YoY; gross margin 28% (from year-end 2025); specific dollar figures not disclosed.
Risk Factors
- Distant development timeline for Emperor platform (IDE 2028, clinical 2029) limits near-term catalyst.
- Leadership transitions (Interim CEO) create execution risk.
- Capital structure amendments could lead to shareholder dilution.
- Low institutional ownership (top holders <$90K) suggests limited institutional support.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PMI) — Batch item 1 | 0001437749-26-022398 |
| Exhibit: ex_984075.htm | 0001437749-26-022399 |
| Document: 0001437749-26-022398-index-headers.html | 0001437749-26-022398 |
| Document: 0001437749-26-022398-index.html | 0001437749-26-022398 |
| Document: 0001437749-26-022398.txt | 0001437749-26-022398 |
| 425 Filing (PMI) — Batch item 6 | 0001437749-26-022399 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $7.09 | awaiting T+60 | — | $6.61 (−6.77%) |
Oct 22, 2026 4d ago | S-3 | $7.37 | awaiting T+60 | — | $6.61 (+10.31%) |
Oct 6, 2026 20d ago | 8-K | $8.74 | awaiting T+60 | — | $6.61 (+24.37%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.61 (+7428.47%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.61 (+4031.25%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.61 (+4306.67%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.61 (+3802.01%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.61 (+4139.90%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.61 (−51.04%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.61 (+51.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers